BREAKING
Tempus AI to Buy Personalis
0
B
enterprise value
0
$
per share
0
%
premium vs 30-day VWAP
From Partners to Full Ownership
1
2023 collaboration
↓
2
2024 $36M investment
↓
3
2026 acquisition
An End-to-End Oncology Platform
Tempus AI
platform
●
AI multimodal data
●
Paige, Ambry Genetics
●
Diagnosis to treatment
Personalis
MRD
●
NeXT Personal Dx
●
Liquid biopsy ctDNA
●
Recurrence monitoring
0
M
Q2 revenue $
0
clinical tests
0
%
sequential growth
Closing Late 2026 or Early 2027
AI NEWS BLITZ
Tempus AI has agreed to acquire cancer-testing firm Personalis in an all-stock deal.